REG - Tissue Regenix Group - Exercise of Options, Director Dealing and TVR
18/06/2024 17:30
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240618:nRSR9417Sa&default-theme=true
RNS Number : 9417S Tissue Regenix Group PLC 18 June 2024
Tissue Regenix Group plc
('Tissue Regenix', the 'Group', or the 'Company')
Exercise of Options, Director Dealing and Total Voting Rights
Tissue Regenix Group plc (AIM: TRX), the regenerative medical devices company,
announces that the Company has issued and allotted 821,167 new ordinary shares
of 0.1 pence each ("Ordinary Shares") following the exercise of an aggregate
number of 821,167 share options (the "Options") by Daniel Lee (Chief Executive
Officer), David Cocke (Chief Financial Officer), Kirsten Lund (PDMR) and other
employees, issued under the Company's Long-Term Incentive Plan. Each employee
disposed of such number of Ordinary Shares required to cover the associated
cost attached to the exercise of Options.
Numer of Options exercised Numbers of Ordinary Shares sold Price of Ordinary Shares sold Resultant beneficial holding % of issued share capital
Daniel Lee 283,216 87,611 61 pence 282,512 0.4
David Cocke 146,491 63,207 61 pence 154,489 0.2
Kirsten Lund 109,091 60,751 61 pence 113,557 0.2
Application has been made for the 821,167 new Ordinary Shares to be admitted
to trading on AIM. It is expected that dealings in these new Ordinary Shares
will commence at 8.00 a.m. on 27 June 2024. The new Ordinary Shares will rank
pari passu with the existing Ordinary Shares.
Following Admission, the Company will have in issue a total of 71,395,635
Ordinary Shares. The Company does not hold any Ordinary Shares in treasury.
Therefore, the number of total voting rights for the Company will be
71,395,635.
For more information:
Tissue Regenix Group plc www.tissueregenix.com (http://www.tissueregenix.com)
David Cocke, Chief Financial Officer via Walbrook PR
Cavendish Capital Markets Limited (Nominated Adviser and Broker)
Emily Watts/Geoff Nash/George Dollemore - Corporate Finance
Nigel Birks/Harriet Ward - ECM
Walbrook PR (Financial PR and IR) Tel: +44 (0)20 7933 8780
Alice Woodings/Charlotte Edgar TissueRegenix@walbrookpr.com
About Tissue Regenix (www.tissueregenix.com (http://www.tissueregenix.com) )
Tissue Regenix is a leading medical device company in regenerative medicine.
The Company's patented decellularisation technology (dCELL®) removes DNA and
other cellular material from animal and human soft tissue, leaving an
acellular tissue scaffold not rejected by the patient's body that can be used
to repair diseased or damaged body structures. Current applications address
many crucial clinical needs in sports medicine, foot and ankle injuries, and
wound care.
In August 2017, Tissue Regenix acquired CellRight Technologies®. This
biotech company specialises in regenerative medicine and is dedicated to
developing high-quality, innovative tissue scaffolds to enhance healing
opportunities in defects created by trauma and disease. CellRight's human
tissue products may be used in spine, trauma, general orthopaedic, dental and
ophthalmological surgical procedures.
Further details of the PDMR dealing are included below. This information has
been provided in accordance with Article 5(1)(b) of the Market Abuse
Regulation (EU) No 596/2014 which is part of UK law by virtue of the European
Union (Withdrawal) Act 2018.
1. Details of the person discharging managerial responsibilities / person closely
associated
a) Name Daniel Lee
2. Reason for the Notification
a) Position/status Chief Executive Officer
b) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Tissue Regenix Group plc
b) LEI 213800PNOD5UHQUFJI36
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the Financial instrument, type of instrument
Ordinary Shares of 0.1p each
Identification code GB00B5SGVL29
b) Nature of the transaction Exercise of options and sale of Ordinary Shares
c) Price(s) and volume(s) Options exercised: 283,216 Ordinary Shares at an exercise price of 10 pence
each
Ordinary Shares sold: 87,611 shares at 61 pence each
d) Aggregated information:
· Aggregated volume N/A
· Price
e) Date of the transaction 18 June 2024
f) Place of the transaction London Stock Exchange, AIM Market
3.
Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a)
Name
Tissue Regenix Group plc
b)
LEI
213800PNOD5UHQUFJI36
4.
Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a)
Description of the Financial instrument, type of instrument
Ordinary Shares of 0.1p each
Identification code
GB00B5SGVL29
b)
Nature of the transaction
Exercise of options and sale of Ordinary Shares
c)
Price(s) and volume(s)
Options exercised: 283,216 Ordinary Shares at an exercise price of 10 pence
each
Ordinary Shares sold: 87,611 shares at 61 pence each
d)
Aggregated information:
· Aggregated volume
· Price
N/A
e)
Date of the transaction
18 June 2024
f)
Place of the transaction
London Stock Exchange, AIM Market
1. Details of the person discharging managerial responsibilities / person closely
associated
a) Name David Cocke
2. Reason for the Notification
a) Position/status Chief Financial Officer
b) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Tissue Regenix Group plc
b) LEI 213800PNOD5UHQUFJI36
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the Financial instrument, type of instrument
Ordinary Shares of 0.1p each
Identification code GB00B5SGVL29
b) Nature of the transaction Exercise of options and sale of Ordinary Shares
c) Price(s) and volume(s) Options exercised: 146,491 Ordinary Shares at an exercise price of 10 pence
each
Ordinary Shares sold: 63,207 shares at 61 pence each
d) Aggregated information:
· Aggregated volume N/A
· Price
e) Date of the transaction 18 June 2024
f) Place of the transaction London Stock Exchange, AIM Market
3.
Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a)
Name
Tissue Regenix Group plc
b)
LEI
213800PNOD5UHQUFJI36
4.
Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a)
Description of the Financial instrument, type of instrument
Ordinary Shares of 0.1p each
Identification code
GB00B5SGVL29
b)
Nature of the transaction
Exercise of options and sale of Ordinary Shares
c)
Price(s) and volume(s)
Options exercised: 146,491 Ordinary Shares at an exercise price of 10 pence
each
Ordinary Shares sold: 63,207 shares at 61 pence each
d)
Aggregated information:
· Aggregated volume
· Price
N/A
e)
Date of the transaction
18 June 2024
f)
Place of the transaction
London Stock Exchange, AIM Market
1. Details of the person discharging managerial responsibilities / person closely
associated
a) Name Kirsten Lund
2. Reason for the Notification
a) Position/status PDMR
b) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Tissue Regenix Group plc
b) LEI 213800PNOD5UHQUFJI36
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the Financial instrument, type of instrument
Ordinary Shares of 0.1p each
Identification code GB00B5SGVL29
b) Nature of the transaction Exercise of options and sale of Ordinary Shares
c) Price(s) and volume(s) Options exercised: 109,091 Ordinary Shares at an exercise price of 10 pence
each
Ordinary Shares sold: 60,751 shares at 61 pence each
d) Aggregated information:
· Aggregated volume N/A
· Price
e) Date of the transaction 18 June 2024
f) Place of the transaction London Stock Exchange, AIM Market
3.
Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a)
Name
Tissue Regenix Group plc
b)
LEI
213800PNOD5UHQUFJI36
4.
Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a)
Description of the Financial instrument, type of instrument
Ordinary Shares of 0.1p each
Identification code
GB00B5SGVL29
b)
Nature of the transaction
Exercise of options and sale of Ordinary Shares
c)
Price(s) and volume(s)
Options exercised: 109,091 Ordinary Shares at an exercise price of 10 pence
each
Ordinary Shares sold: 60,751 shares at 61 pence each
d)
Aggregated information:
· Aggregated volume
· Price
N/A
e)
Date of the transaction
18 June 2024
f)
Place of the transaction
London Stock Exchange, AIM Market
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHQVLFFZQLFBBZRecent news on Tissue Regenix
See all newsREG - Tissue Regenix Group - Grant of share options
AnnouncementREG - Tissue Regenix Group - Half-Year Trading Update
AnnouncementREG - Tissue Regenix Group - Holding(s) in Company
AnnouncementREG - Tissue Regenix Group - Holding(s) in Company
AnnouncementREG - AIM - AIM Notice - 24/06/2024
Announcement